Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9162003 | 0.93 | HPGD (0.47) | HPGDEPHX2CYP2D6CYP2C19RECQL | |
| SCHEMBL9153250 | 0.93 | HPGD (0.47) | HPGDEPHX2CYP2D6CYP2C19RECQL | |
| SCHEMBL16473882 | 0.88 | CYP2D6 (0.46) | HPGDEPHX2CYP2D6CYP2C19RECQL | |
| SCHEMBL20034806 | 0.87 | EPHX2 (0.47) | HPGDEPHX2CYP2D6CYP2C19RECQL | |
| SCHEMBL24891029 | 0.82 | HPGD (0.43) | HPGDEPHX2CYP2D6CYP2C19RECQL | |
| SCHEMBL20206734 | 0.81 | CYP2D6 (0.41) | HPGDEPHX2CYP2D6CYP2C19RECQL | |
| SCHEMBL24450393 | 0.81 | HPGD (0.38) | HPGDEPHX2RECQL | |
| SCHEMBL21015912 | 0.78 | RECQL (0.42) | RECQLSMN1; SMN2MAPT | |
| SCHEMBL17664597 | 0.78 | FAAH (0.57) | HPGDEPHX2RECQLSMN1; SMN2 | |
| SCHEMBL11438194 | 0.78 | RECQL (0.47) | HPGDRECQLSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | HPGD 3809/4885EPHX2 1940/4885CYP2D6 2165/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | HPGD 3953/4885EPHX2 2154/4885CYP2D6 2300/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | HPGD 3809/4885EPHX2 1940/4885CYP2D6 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.